Meropenem
| Drug Category | Drug | IHD Dosing |
Administration Timing Around HD Session |
|---|---|---|---|
| Antibiotics | Meropenem | 500-1000mg IV Q24H | Administer Post-HD |
|
Molecular Weight (Da) | Excreted Unchanged (%) | Normal Half-Life (Hours) | ESRD Half-Life (Hours) | Plasma Protein Binding (%) | Volume of Distribution (L/kg) | Dialytic Plasma Clearance (ml/min) | % Dialyzed |
|---|---|---|---|---|---|---|---|
| 383 | 65 | 1.1 | 6-8 | 2 | 0.35 | 19-25 | 50-70 (low flux) |
References:
- Aronoff GR, Bennett WM, Berns JS, Brier ME, Kasbekar N, Mueller BA, et al. Drug Prescribing in Renal Failure. Philadelphia: American College of Physicians;2007.
- Chimata M, Nagase M, Suzuki Y, Shimomura M, Kakuta S. Pharmacokinetics of meropenem in patients with various degrees of renal function, including patients with end-stage renal disease. Antimicrobial agents and chemotherapy 1993; 37(2), 229-34.
- Christensson B, Nilsson-Ehle L, Hutchinson M, Haworth S, Oqvist B, Norrby S. Pharmacokinetics of Meropenem in Subjects with Various Degrees of Renal Impairment. Antimicrobial agents and chemotherapy 1992; 36(7), 1532-8.
- DrugBank [Online]. 2012 Apr 12 [cited 2012 May 6]; Available from: URL: http://www.drugbank.ca/drugs/DB00760
- Heintz B, Matzke G, Dager W. Antimicrobial dosing concepts and recommendations for critically ill adult patients receiving continuous renal replacement therapy or intermittent hemodialysis. Pharmacotherapy 2009; 29(5), 562-77.
- Leroy A, Fillastre J, Etienne L, Borsa-Lebás F, Humbert G. Pharmacokinetics of meropenem in subjects with renal insufficiency. European journal of clinical pharmacology 1992; 42(5), 535-8.
- Leroy A, Fillastre J, Etienne L, Humbert G. Pharmacokinetics of Meropenem (ICI 194, 660) and Its Metabolite (ICI 213, 689) in Healthy Subjects and in Patients with Renal Impairment. Antimicrobial agents and chemotherapy 1992; 36(12), 2794-9.
- Matzke G. Status of Hemodialysis of Drugs in 2002. Journal of Pharmacy Practice 2002; 15(5), 405-418.
- Thalhammer F, Hörl W. Pharmacokinetics of meropenem in patients with renal failure and patients receiving renal replacement therapy. Clinical pharmacokinetics 2000; 39(4), 271-9.